Keywords: Type 2 diabetes market, Decision Resources, Merck & C o, Januvia, Eli Lilly, Byetta, Bydureon, Taspoglutide, Roche, Ipsen

Type 2 diabetes drug market to nearly double to $36 billion in 2019, boosted by news drugs; research shows many patients not taking their insulin

Article | 23 September 2010

Print This

The continued uptake of key agents such as Merck & Co's Januvia (sitagliptin), Amylin/Eli Lilly's Byetta (exenatide) and Lilly/ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in